162 related articles for article (PubMed ID: 30105440)
1. Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Okumura Y; Noda T; Eguchi H; Sakamoto T; Iwagami Y; Yamada D; Asaoka T; Wada H; Kawamoto K; Gotoh K; Kobayashi S; Takeda Y; Tanemura M; Umeshita K; Doki Y; Mori M
Ann Surg Oncol; 2018 Nov; 25(12):3728-3737. PubMed ID: 30105440
[TBL] [Abstract][Full Text] [Related]
2. ASO Author Reflections: Hypoxia-Induced PLOD2 Is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Okumura Y; Eguchi H
Ann Surg Oncol; 2018 Nov; 25(12):3738-3739. PubMed ID: 30167909
[No Abstract] [Full Text] [Related]
3. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer.
Yamada D; Kobayashi S; Wada H; Kawamoto K; Marubashi S; Eguchi H; Ishii H; Nagano H; Doki Y; Mori M
Eur J Cancer; 2013 May; 49(7):1725-40. PubMed ID: 23298711
[TBL] [Abstract][Full Text] [Related]
4. BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.
Nakashima S; Kobayashi S; Nagano H; Tomokuni A; Tomimaru Y; Asaoka T; Hama N; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
Cancer Sci; 2015 May; 106(5):584-91. PubMed ID: 25736055
[TBL] [Abstract][Full Text] [Related]
5. PLOD2 as a potential regulator of peritoneal dissemination in gastric cancer.
Kiyozumi Y; Iwatsuki M; Kurashige J; Ogata Y; Yamashita K; Koga Y; Toihata T; Hiyoshi Y; Ishimoto T; Baba Y; Miyamoto Y; Yoshida N; Yanagihara K; Mimori K; Baba H
Int J Cancer; 2018 Sep; 143(5):1202-1211. PubMed ID: 29603227
[TBL] [Abstract][Full Text] [Related]
6. Identification and Validation of PLOD2 as an Adverse Prognostic Biomarker for Oral Squamous Cell Carcinoma.
Sun Y; Wang S; Zhang X; Wu Z; Li Z; Ding Z; Huang X; Chen S; Jing Y; Zhang X; Ding L; Song Y; Sun G; Ni Y
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944486
[TBL] [Abstract][Full Text] [Related]
7. Effect of midkine on gemcitabine resistance in biliary tract cancer.
Lu Y; Yan B; Guo H; Qiu L; Sun X; Wang X; Shi Q; Bao Y
Int J Mol Med; 2018 Apr; 41(4):2003-2011. PubMed ID: 29344648
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significances of PLOD2, epithelial-mesenchymal transition markers, and cancer stem cells in patients with esophageal squamous cell carcinoma.
Gong X; Wang A; Song W
Medicine (Baltimore); 2022 Aug; 101(34):e30112. PubMed ID: 36042592
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-induced PLOD2 regulates invasion and epithelial-mesenchymal transition in endometrial carcinoma cells.
Wan J; Qin J; Cao Q; Hu P; Zhong C; Tu C
Genes Genomics; 2020 Mar; 42(3):317-324. PubMed ID: 31872384
[TBL] [Abstract][Full Text] [Related]
10. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of Treg/Th17 According to Cancer Progression and Modification in Biliary Tract Cancers via Self-Producing Cytokines.
Kinoshita M; Kobayashi S; Gotoh K; Kubo M; Hayashi K; Iwagami Y; Yamada D; Akita H; Noda T; Asaoka T; Takeda Y; Tanemura M; Eguchi H; Urakawa S; Goto K; Maekawa K; Wada H; Mori M; Doki Y
Dig Dis Sci; 2020 Oct; 65(10):2937-2948. PubMed ID: 31853779
[TBL] [Abstract][Full Text] [Related]
12. A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.
Sakamoto T; Kobayashi S; Yamada D; Nagano H; Tomokuni A; Tomimaru Y; Noda T; Gotoh K; Asaoka T; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
PLoS One; 2016; 11(1):e0145985. PubMed ID: 26726879
[TBL] [Abstract][Full Text] [Related]
13. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
14. PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection.
Noda T; Yamamoto H; Takemasa I; Yamada D; Uemura M; Wada H; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
Liver Int; 2012 Jan; 32(1):110-8. PubMed ID: 22098155
[TBL] [Abstract][Full Text] [Related]
15. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
Nakamura J; Kohya N; Kai K; Ohtaka K; Hashiguchi K; Hiraki M; Kitajima Y; Tokunaga O; Noshiro H; Miyazaki K
Int J Oncol; 2010 Oct; 37(4):845-52. PubMed ID: 20811706
[TBL] [Abstract][Full Text] [Related]
16. ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer.
Ueno G; Iwagami Y; Kobayashi S; Mitsufuji S; Yamada D; Tomimaru Y; Akita H; Asaoka T; Noda T; Gotoh K; Mori M; Doki Y; Eguchi H
Ann Surg Oncol; 2022 May; 29(5):2899-2909. PubMed ID: 34994902
[TBL] [Abstract][Full Text] [Related]
17. [Mechanism of PLOD2 induced osimertinib resistance in non-small cell lung cancer HCC827 cells].
Kang XH; Wang K; Wang Y; Zhao HK; Zhang J; Zhao KL; Miao ZH; Xu ZY; Cao F; Gong YB
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):210-215. PubMed ID: 32252199
[No Abstract] [Full Text] [Related]
18. Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma.
Song Y; Zheng S; Wang J; Long H; Fang L; Wang G; Li Z; Que T; Liu Y; Li Y; Zhang X; Fang W; Qi S
Oncotarget; 2017 Jun; 8(26):41947-41962. PubMed ID: 28410212
[TBL] [Abstract][Full Text] [Related]
19. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
Kim J; Kim H; Lee JC; Kim JW; Paik WH; Lee SH; Hwang JH; Ryu JK; Kim YT
PLoS One; 2018; 13(12):e0209104. PubMed ID: 30557411
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.
Yokoyama T; Yoshida H; Makino H; Maruyama H; Suzuki S; Matsutani T; Matsushita A; Hirakata A; Sasajima K; Uchida E
J Nippon Med Sch; 2012; 79(3):204-12. PubMed ID: 22791122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
